Scientists from Volgograd and Rostov-on-Don have examined a new chemical compound that can positively affect disordered carbohydrate metabolism in a human body with sugar diabetes, the website of the Commission on Modernization and Technological Development of Economy of Russia i-russia.ru reports.

Efficiency of the new substance is in its ability to differently influence several factors, facilitating development of the pathology, such as the level of insulin in blood.

Depending on the functional activity of beta-cells (they are responsible for insulin generation) of pancreas of a specific patient and degree of disorder of carbohydrate metabolism, the new molecule can restore norm level of insulin secretion and strengthen release of this sugar-lowering hormone.

What is of special value is that at the same time the level of glucose in blood due to expressed peripheral action that improves utilization of glucose by tissue-targets.

One of principal differences of the new molecule is that besides lowering sugar in blood, it also lowers blood viscosity and aggregation of form blood elements and improves microcirculation in tissues. This provides opportunity for preventing risk of development heavy vascular complications at late stages of the disease, when necrosis appear at peripheral parts.

Scientists of the Volgograd State Medical University and the Science and Research Institute of Physics and Organic Chemistry of the Southern Federal are working on development of this direction. The chemists synthesize this substance, while the specialists of the Department of Pharmacology test their impact on live organisms and create optimal clinical form of the synthesized substance using computer technologies and animal testing.

In addition, the scientists have discovered new perspective molecules that influence reasons of emergence of the second-type diabetes, giving hope to obtaining another substance. The scientists have carried out comprehensive complex of research of the perspective molecule, tested toxic impact and received authorization on clinical testing.